Literature DB >> 27182039

A novel mutation in FBXL4 in a Norwegian child with encephalomyopathic mitochondrial DNA depletion syndrome 13.

Tuva Barøy1, Christeen Ramane J Pedurupillay2, Yngve T Bliksrud3, Magnhild Rasmussen4, Asbjørn Holmgren5, Magnus D Vigeland6, Timothy Hughes7, Maaike Brink8, Richard Rodenburg9, Bård Nedregaard10, Petter Strømme11, Eirik Frengen12, Doriana Misceo13.   

Abstract

Mitochondrial DNA depletion syndromes (MTDPS) represent a clinically and genetically heterogeneous group of autosomal recessive disorders, caused by mutations in genes involved in maintenance of mitochondrial DNA (mtDNA). Biallelic mutations in FBXL4 were recently described to cause encephalomyopathic MTDPS13. The syndrome has infantile onset and presents with hypotonia, feeding difficulties, a pattern of mild facial dysmorphisms, global developmental delay and brain atrophy. Laboratory investigations reveal elevated blood lactate levels, unspecific mitochondrial respiratory chain (MRC) enzyme deficiencies and mtDNA depletion. We report a novel missense variant, c.1442T > C (p.Leu481Pro), in FBXL4 (NM_012160.4) in a Norwegian boy with clinical, biochemical and cerebral MRI characteristics consistent with MTDPS13. The FBXL4 c.1442T > C (p.Leu481Pro) variant was not present in public databases, 149 Norwegian controls nor an in-house database containing whole exome sequencing data from 440 individuals, and it was predicted in silico to be deleterious to the protein function. Activities of MRC enzymes were normal in muscle tissue (complexes I-IV) and cultured skin fibroblasts (complexes I-V) from the patient, but mtDNA depletion was confirmed in muscle, thus supporting the predicted pathogenicity of the FBXL4 c.1442T > C (p.Leu481Pro) variant. On clinical indication of mitochondrial encephalomyopathy, sequencing of FBXL4 should be performed, even when the activity levels of the MRC enzymes are normal.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  FBXL4; MTDPS13; Mitochondrial disorder; c.1442T>C; mtDNA depletion; p.Leu481Pro

Mesh:

Substances:

Year:  2016        PMID: 27182039     DOI: 10.1016/j.ejmg.2016.05.005

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  5 in total

1.  Hyperammonemia as a Presenting Feature in Two Siblings with FBXL4 Variants.

Authors:  Sarah U Morton; Edward G Neilan; Roy W A Peake; Jiahai Shi; Klaus Schmitz-Abe; Meghan Towne; Kyriacos Markianos; Sanjay P Prabhu; Pankaj B Agrawal
Journal:  JIMD Rep       Date:  2016-11-18

2.  A Mild Phenotype of Mitochondrial DNA Depletion Syndrome Type 13 with a Novel FBXL4 Variant.

Authors:  Ummuhan Oncul; Engin Kose; Fatma Tuba Eminoglu
Journal:  Mol Syndromol       Date:  2021-07-19

3.  FBXL4-Related Mitochondrial DNA Depletion Syndrome 13 (MTDPS13): A Case Report With a Comprehensive Mutation Review.

Authors:  Rami A Ballout; Chadi Al Alam; Penelope E Bonnen; Martina Huemer; Ayman W El-Hattab; Rolla Shbarou
Journal:  Front Genet       Date:  2019-02-05       Impact factor: 4.599

Review 4.  Mitochondrial Dynamics: Molecular Mechanisms, Related Primary Mitochondrial Disorders and Therapeutic Approaches.

Authors:  Michela Di Nottia; Daniela Verrigni; Alessandra Torraco; Teresa Rizza; Enrico Bertini; Rosalba Carrozzo
Journal:  Genes (Basel)       Date:  2021-02-10       Impact factor: 4.096

Review 5.  Mitochondrial DNA Depletion Syndrome and Its Associated Cardiac Disease.

Authors:  Haiying Wang; Yijun Han; Shenwei Li; Yunan Chen; Yafen Chen; Jing Wang; Yuqing Zhang; Yawen Zhang; Jingsuo Wang; Yong Xia; Jinxiang Yuan
Journal:  Front Cardiovasc Med       Date:  2022-02-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.